The India tuberculosis treatment market was valued at USD 397.63 Million in 2025, driven by the rising focus on multidrug-resistant tuberculosis management and robust government initiatives in the region. The market is anticipated to grow at a CAGR of 4.20% during the forecast period of 2026-2035, with the values likely to reach USD 600.01 Million by 2035. The expanding access to free diagnostics and treatment under national programs, along with growing adoption of rapid molecular tests and digital adherence technologies for improved TB care, are likely to drive the market growth in the forecast period.
Base Year
Historical Period
Forecast Period
One of the key trends shaping the tuberculosis treatment market in India is the growing focus on managing drug-resistant tuberculosis.
Technological advancements in diagnostics, such as the availability of tools like GeneXpert and TrueNat, are projected to elevate India tuberculosis treatment market.
The rise in public-private collaboration and increasing public awareness are expected to support market expansion in the country.
Compound Annual Growth Rate
4.2%
Value in USD Million
2026-2035
*this image is indicative*
The market is expected to grow significantly in the coming years, driven by government efforts, advances in drug development, and increased public awareness. The rise of drug-resistant tuberculosis is likely to augment demand for second-line therapies, while first-line treatments will remain the backbone of the national TB control strategy. With proactive government measures, ongoing collaborations, and technological innovations, the market is projected to positively impact the market dynamics in the forecast period.
Rising Tuberculosis Incidence to Boost Market Growth in India
According to the World Health Organization's Global Tuberculosis Report 2023, India remains the country with the highest tuberculosis burden globally, representing 26% of the world’s total tuberculosis cases. The report also reveals that 2.8 million new TB cases were reported in India in 2023, with the incidence rate estimated to be 195 per 1,00,000 individuals. This high incidence of tuberculosis in India is significantly driving the demand for both first-line and second-line therapies, thereby boosting market growth.
The market is witnessing several trends, including a rising focus on combating drug-resistant tuberculosis, supported by proactive government initiatives.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Therapy
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
The First-Line Therapy Segment Expected to Dominate the Market Share
Based on therapy, the market is segmented into first-line therapy and second-line therapy. First-line therapy is expected to hold a substantial market share due to its owing to its widespread use in treating drug-sensitive tuberculosis. This therapy typically includes a combination of rifampicin, isoniazid, ethambutol, and pyrazinamide. As these drugs have been in use for decades, they are readily available and cost-effective, making them a crucial part of India’s National Tuberculosis Elimination Programme (NTEP).
In India, Uttar Pradesh accounts for a significant portion of India's tuberculosis treatment volumes, particularly in the private sector. This Indian state is a priority for targeted interventions and public health initiatives, owing to its large population and tuberculosis burden. Further, Maharashtra also holds a high market value. The state has implemented successful strategies to engage private healthcare providers in tuberculosis care, improving treatment outcomes, and is anticipated to support market expansion.
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi plays a significant role in the Indian market through its supply of essential anti-tuberculosis drugs. It has historically been a key manufacturer of rifampicin-based formulations, which are central to the standard tuberculosis treatment regimen. Sanofi also works closely with various public health initiatives to ensure the availability and affordability of tuberculosis medications in India, particularly in resource-limited settings.
Pfizer contributes to the India tuberculosis treatment market growth through its broader work in infectious diseases and health system support. The company has invested in strengthening disease awareness, diagnostics, and infrastructure, which indirectly benefits TB detection and management. Pfizer’s portfolio of anti-infectives and vaccines supports comorbidity management and prevention of secondary infections in TB patients.
Johnson & Johnson, through its pharmaceutical arm Janssen, is a key player in the treatment of multidrug-resistant tuberculosis (MDR-TB) in India. The company’s drug bedaquiline, one of the first new anti-TB medications in decades, has been endorsed by the WHO and adopted in India’s national treatment guidelines.
Novartis AG is a global leader in the pharmaceutical industry, known for its portfolio in oncology, cardiovascular diseases, ophthalmology, and immunology. While Novartis does not have a direct tuberculosis drug in its primary commercial portfolio, it still plays an important role in the fight against tuberculosis, particularly through global health initiatives. Novartis has been actively involved in public-private partnerships and research collaborations focused on neglected diseases, including tuberculosis.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include GlaxoSmithKline plc, Merck & Co., Inc., Lupin, Cipla Ltd., Macleods Pharmaceuticals Ltd., and Sun Pharmaceutical Industries Ltd.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Therapy |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share